ITCI 📈 Intracellular Th - Overview

Intra-Cellular Therapies, a biopharmaceutical company, is dedicated to developing and commercializing small molecule drugs that target intracellular signaling mechanisms in the central nervous system (CNS) to address significant medical needs in neuropsychiatric and neurological disorders. By focusing on the complex interactions within cells, the company aims to create innovative treatments that can effectively manage debilitating conditions such as schizophrenia, bipolar depression, and various depressive disorders. Its lead product, CAPLYTA, has already been approved for the treatment of schizophrenia and bipolar depression in adults, demonstrating the company's ability to bring novel therapies to market.

Building on this success, Intra-Cellular Therapies is advancing a robust pipeline of candidates, including Lumateperone, which is currently in Phase 3 clinical trials for the treatment of depressive disorders and other neuropsychiatric indications. The company is also developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, as well as other CNS and neurological disorders. Additionally, ITI-1284 and ITI-333 are being investigated for their potential in treating neuropsychiatric disorders, behavioral disturbances in dementia, substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. This diversified pipeline underscores the company's commitment to addressing the complex and interconnected needs of patients with CNS disorders.

With a strong foundation in research and development, Intra-Cellular Therapies has established itself as a key player in the biopharmaceutical industry. Founded in 2002 and headquartered in New York, New York, the company has built a reputation for its rigorous scientific approach and patient-centric focus. As a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol ITCI, Intra-Cellular Therapies is well-positioned to continue advancing its pipeline and delivering innovative treatments to patients in need. With its common stock listed under the ISIN US46116X1019 and classified under the GICS Sub Industry: Pharmaceuticals, the company is poised for long-term growth and success in the pharmaceutical sector.